Benign Prostatic Hyperplasia: Pathophysiology and the Role of DHT in Prostate Enlargement
Benign prostatic hyperplasia (BPH) affects an estimated 50% of men by age 60, and understanding its underlying mechanisms is critical for both prevention and informed treatment decisions. The TriCountyUrology.org Medical Team examines the cellular and hormonal processes that drive prostate enlargement, with particular focus on dihydrotestosterone (DHT) and the 5-alpha-reductase enzyme system.
The Prostate: Normal Structure and Function
The prostate is a walnut-sized gland that surrounds the urethra and plays a key role in reproductive health. In normal aging, the prostate can gradually enlarge due to accumulation of epithelial and stromal cells—a process distinct from cancerous growth. This benign enlargement becomes clinically significant when it obstructs urine flow or triggers storage symptoms like urgency and frequency.
Histological studies show that BPH involves both hyperplasia (increased cell number) and hypertrophy (increased cell size), primarily in the transition zone surrounding the urethra. This anatomical location explains why even moderate enlargement can cause urinary symptoms.
Dihydrotestosterone: The Primary Driver
Testosterone, while not the direct cause of BPH, plays a permissive role. The enzyme 5-alpha-reductase converts testosterone into dihydrotestosterone (DHT), a more potent androgen that accumulates in prostate tissue and binds to androgen receptors on stromal and epithelial cells. Research suggests that DHT stimulates growth factor production and reduces apoptosis (programmed cell death), leading to net cell accumulation over time.
Notably, men who lack functional 5-alpha-reductase or who are castrated before puberty do not develop BPH, highlighting DHT's central pathophysiologic role. There are two isoforms of 5-alpha-reductase: Type 1 (found in skin and liver) and Type 2 (predominant in prostate). Type 2 appears to have greater significance in BPH development, which explains why 5-alpha-reductase inhibitors (finasteride, dutasteride) specifically target this pathway.
Growth Factor Pathways and Stromal-Epithelial Interactions
Beyond DHT, BPH involves complex signaling networks. Transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), and insulin-like growth factor (IGF) may all contribute to cellular proliferation. The stromal compartment—comprising smooth muscle, fibroblasts, and extracellular matrix—appears particularly important in BPH pathogenesis. Stromal cells produce growth factors that stimulate epithelial proliferation, suggesting a coordinated dialogue between tissue compartments.
Chronic inflammation within prostate tissue has emerged as an additional factor. Infiltration of CD8+ T cells and macrophages, along with elevated cytokine levels (IL-6, IL-8, TNF-α), may perpetuate a low-grade inflammatory state that promotes cell proliferation and survival.
Age-Related Changes and Stem Cell Dynamics
Age is the strongest risk factor for BPH. As men age, prostate tissue accumulates senescent cells—cells that have lost the ability to divide but remain metabolically active and produce pro-inflammatory mediators. This senescent cell burden may shift the balance toward proliferation and away from cell death, allowing enlarged prostate tissue to persist.
Additionally, stem cell populations within the prostate may undergo changes that increase their proliferative capacity or reduce their ability to differentiate properly. These age-related alterations in tissue homeostasis may explain why BPH is rare in young men but nearly universal in older men.
Genetics and Individual Susceptibility
Twin studies suggest heritability of BPH in approximately 45% of cases, indicating substantial genetic influence. Candidate genes include those encoding growth factors, estrogen receptors, and inflammatory mediators. Men with a family history of BPH or early-onset prostate symptoms face increased risk, though environmental factors also play a role.
Polymorphisms in genes such as SRD5A2 (encoding 5-alpha-reductase type 2) and AR (androgen receptor) have been associated with BPH severity in some populations, though findings have not been entirely consistent across studies.
Obesity, Metabolic Syndrome, and Insulin Signaling
Epidemiological evidence links obesity and metabolic syndrome to more severe BPH. Adipose tissue produces inflammatory cytokines, and insulin resistance may enhance growth factor signaling in prostate tissue. The metabolic environment may amplify proliferative pathways, making overweight men more susceptible to symptomatic BPH.
The Role of Estrogens
While testosterone and DHT are the primary hormonal drivers, estrogen also appears relevant. With aging, the testosterone-to-estrogen ratio shifts, and estrogens may sensitize the prostate to DHT effects or independently promote stromal proliferation. The balance of hormonal signals thus shifts with advancing age, potentially accelerating growth.
Apoptosis Resistance and Reduced Cell Death
Normal tissue homeostasis requires a balance between cell proliferation and programmed cell death (apoptosis). In BPH, there is evidence for reduced apoptosis in both epithelial and stromal compartments. Anti-apoptotic proteins such as Bcl-2 are upregulated, while pro-apoptotic signals may be dampened. This shift favors cell accumulation and tissue expansion.
Clinical Implications of Pathophysiology
Understanding BPH pathophysiology explains why different treatment approaches target different pathways. 5-alpha-reductase inhibitors address the DHT-driven component, while alpha-adrenergic blockers primarily reduce smooth muscle tone rather than addressing cellular proliferation. Combination therapy may be more effective for men with significant cellular enlargement and substantial smooth muscle contribution.
Emerging research on anti-inflammatory and anti-apoptotic approaches—including botanical compounds and lifestyle modifications—reflects growing recognition that BPH involves multiple biological pathways beyond androgen signaling alone.
Disclaimer: This article is for educational purposes and should not be construed as medical advice. Readers with prostate symptoms should consult a urologist for proper diagnosis and individualized treatment recommendations. Published by TriCountyUrology.org Medical Team, July 2026.
Related Resources: Explore prostate health supplement evidence, safety considerations with prostate supplements and medications, and the relationship between testosterone and prostate health.